Use and Persistence of Beta 3‐Adrenoceptor Agonists for the Treatment of Overactive Bladder
The higher discontinuation rate of mirabegron may reflect the availability of vibegron as an alternative treatment option. The complementary use of both β3 agonists could play a key role in optimizing OAB management.
Authors
- Hajime Ishida (ORCID: https://orcid.org/0000-0002-5781-7914)
- Miyu Ohtani
- Kazuyuki Numakura
- Daiki Kikuchi
- Naoki Wada (ORCID: https://orcid.org/0000-0002-9587-6798)
- Kotona Miyauchi
- Rie Takada (ORCID: https://orcid.org/0000-0001-5101-091X)
- N. Abe (ORCID: https://orcid.org/0009-0001-3306-9544)
- Taichiro Ishimaru
Institutions
- Asahikawa Medical University (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2025-12-07
- DOI
- https://doi.org/10.1111/iju.70309
- Citations
- 1
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 1.84